Comparison of Healthcare Resource Utilization Between Patients Who Engaged or Did Not Engage With a Prescription Digital Therapeutic for Opioid Use Disorder.
Fulton Velez,Sam Colman,Laura Kauffman,Charles Ruetsch,Kathryn Anastassopoulos,Yuri A. Maricich +5 more
TLDR
In this paper, the authors compared real-world healthcare resource utilization (HCRU) among patients who engaged with reSET-O and buprenorphine compared to similar patients in recovery who did not fill their reset-O script or engage with the PDT beyond week one.Abstract:
Background A prescription digital therapeutic (PDT) (reSET-O®) may expand access to behavioral treatment for patients with opioid use disorder (OUD) treated with buprenorphine, but long-term data on effectiveness are lacking. Objective To compare real-world healthcare resource utilization (HCRU) among patients who engaged with reSET-O and buprenorphine compared to similar patients in recovery treated with buprenorphine who did not fill their reSET-O script or engage with the PDT beyond week one. Methods A retrospective analysis of facility and clinical service claims data was conducted in adults with PDT initiation and between 12 weeks and 9 months of continuous enrollment in a health plan after initiation. Patients who filled their prescription and engaged with the therapeutic were compared to patients who filled the prescription but did not engage beyond week one (NE), and patients who did not fill the prescription (NR) (the latter two groups combined into one group hereafter referred to as "non-engagers"). Comparisons were analyzed using a repeated-measures negative binomial model of encounters/procedures, adjusted for number of days in each period. Associated cost trends assessed using current Medicare reimbursement rates. Results A total of 444 patients redeemed a prescription and engaged with the PDT (mean age 37.5 years, 63.1% female, 84% Medicaid), and 64 patients did not engage with the PDT (mean age 39.5 years, 32.8% female, 73.4% Medicaid). Total cost of hospital facility encounters was $2693 for engaged patients vs $6130 for non-engaged patients. Engaged patients had somewhat higher rates of certain clinician services. Total facility and clinician services costs for engaged vs non-engaged patients were $8733 vs $11,441, for a net cost savings over 9 months of $2708 per patient who engaged with reSET-O. Conclusion Patients who engaged with an OUD-specific PDT had a net cost reduction for inpatient and outpatient services of $2708 per patient over 9 months compared to patients who did not engage with the PDT, despite similar levels of buprenorphine adherence.read more
Citations
More filters
Journal ArticleDOI
Reduced Healthcare Resource Utilization in Patients with Opioid Use Disorder in the 12 Months After Initiation of a Prescription Digital Therapeutic
Fulton Velez,Kathryn Anastassopoulos,S. Colman,Neel Shah,Laura Kauffman,Sean M. Murphy,Charles Ruetsch,Yuri A. Maricich +7 more
TL;DR: In this paper , an FDA-authorized prescription digital therapeutic (PDT) delivering cognitive behavioral therapy and contingency management to patients with opioid u®se disorder (OUD) may help improve clinical outcomes.
Journal ArticleDOI
Rewarding recovery: the time is now for contingency management for opioid use disorder
TL;DR: An up-to-date overview of the current evidence base for contingency management for opioid use disorder is provided and common barriers and solutions to implementation, as well as implications for future research and clinical practice are discussed.
Journal ArticleDOI
The Rise of Prescription Digital Therapeutics in Behavioral Health
TL;DR: In this article , the use of Prescription Digital Therapeutics (PDTs) for substance use disorder and opioid use disorder is discussed. But, the authors focus on the behavioral dimensions of many diseases and conditions.
Journal ArticleDOI
Acceptability and Usability of a Reward-Based Mobile App for Opioid Treatment Settings: Mixed Methods Pilot Study
TL;DR: This mixed methods pilot study sought to determine the perceived acceptability and usability of PROCare Recovery, a reward-based, technology-enabled recovery monitoring smartphone app designed to automate contingency management by immediately delivering micropays to patients for achieving recovery goals via smart debit card with blocking capabilities.
Journal ArticleDOI
Sociodemographic and Clinical Characteristics Associated with Improvements in Quality of Life for Participants with Opioid Use Disorder
TL;DR: The Houston Emergency Opioid Engagement System was established to create an access pathway into long-term recovery for individuals with opioid use disorder as discussed by the authors , which determines effectiveness across multiple dimensions, one of which is by measuring the participant's reported quality of life (QoL) at the beginning of the program and at successive intervals.
References
More filters
Journal ArticleDOI
Medication Compliance and Persistence: Terminology and Definitions
Joyce A. Cramer,Anuja Roy,Anita Burrell,Carol J. Fairchild,Mahesh J. Fuldeore,Daniel A. Ollendorf,Peter K. Wong +6 more
TL;DR: Providing specific definitions for compliance and persistence is important for sound quantitative expressions of patients' drug dosing histories and their explanatory power for clinical and economic events and adoption by health outcomes researchers will provide a consistent framework and lexicon for research.
Journal ArticleDOI
A Meta-Analytic Review of Psychosocial Interventions for Substance Use Disorders
Lissa Dutra,Georgia Stathopoulou,Shawnee L. Basden,B.A. Teresa M. Leyro,Mark B. Powers,Michael W. Otto +5 more
TL;DR: Overall, controlled trial data suggest that psychosocial treatments provide benefits reflecting a moderate effect size according to Cohen's standards, and these effect sizes are comparable to those for other efficacious treatments in psychiatry.
Journal ArticleDOI
The Economic Burden of Prescription Opioid Overdose, Abuse, and Dependence in the United States, 2013.
TL;DR: These estimates can assist decision makers in understanding the magnitude of adverse health outcomes associated with prescription opioid use such as overdose, abuse, and dependence as well as help decision makers evaluate the cost effectiveness of their choices.
Journal ArticleDOI
Comparative Effectiveness of Different Treatment Pathways for Opioid Use Disorder
Sarah E. Wakeman,Marc R. Larochelle,Marc R. Larochelle,Omid Ameli,Christine E. Chaisson,Jeffrey Thomas McPheeters,William H. Crown,Francisca Azocar,Darshak M. Sanghavi +8 more
TL;DR: Treatment with buprenorphine or methadone was associated with reductions in overdose and serious opioid-related acute care use compared with other treatments, and strategies to address the underuse of MOUD are needed.
Journal ArticleDOI
Changing dynamics of the drug overdose epidemic in the United States from 1979 through 2016
Hawre Jalal,Jeanine M. Buchanich,Mark S. Roberts,Lauren C. Balmert,Lauren C. Balmert,Kun Zhang,Donald S. Burke +6 more
TL;DR: The overall mortality rate for unintentional drug poisonings in the United States grew exponentially from 1979 through 2016, suggesting that the current opioid epidemic may be a more recent manifestation of an ongoing longer-term process.